- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06257043
Safety and Efficacy of Post-marketing Transcatheter Aortic Valves in "Real World" Chinese Patients
RECORD TAVR REGISTRY: Prospective, Multi-Center Registry of "Real World" Chinese Patients Undergoing Transcatheter Aortic Valve Replacement
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aortic stenosis is the most clinically important valvular heart disease in the elderly, with severe aortic stenosis accounting for about 3.4%-5% of elderly patients. Patients with chest pain, congestive heart failure, or syncope who do not undergo surgical intervention have a poor prognosis, with a 1-year mortality rate as high as 50%. However, the high surgical risk of surgical valve replacement for elderly patients with multiple underlying diseases limits the use of surgical valve replacement, and the prognosis of high-risk surgical patients is poor. The PARTNER series of studies and the US CoreValve high-risk studies confirm that perioperative and postoperative adverse events in patients undergoing TAVR in surgical high-risk patients are comparable to those in surgical valve replacement. With technological advances, the indications for TAVR have been expanded from surgical high-risk to low to moderate-risk populations. Based on the PARTNER 3 and Evolut Low Risk studies, FDA approved the use of TAVR to treat low surgical risk patients with symptomatic severe aortic stenosis. Recently, TAVR has also been expanded to patients with aortic valve regurgitation.
With a population of 1.4 billion, China has a large number of patients with aortic valve disease, but the TAVR program was launched in 2010. No large-scale TAVR studies are available to validate the efficacy and safety of TAVR in the Chinese population. The morphological characteristics of valves in our patients bring great challenges to the operation and application of TAVR. However, through the efforts of Chinese experts and scholars, TAVR technology in China has developed rapidly, and various domestic valves with independent intellectual property have been marketed, bringing new opportunities for the promotion and application of TAVR in China. Domestic valves have been designed for the Chinese aortic valve anatomy, which is theoretically more suitable for the Chinese population. However, the efficacy and safety of these valves still need to be further confirmed in large clinical studies.
This multi-center registry study aims to evaluate the safety and efficacy of all post-marketing transcatheter valves in Chinese patients with aortic valve disease mixed. Investigators will collect baseline and procedural data, and evaluate the short-, mid-, and long-term clinical outcomes of TAVR in a large real-world population.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Ruining Zhang, BSc
- Phone Number: +86-15802990370
- Email: ruining-zhang@qq.com
Study Contact Backup
- Name: Rutao Wang, M.D, Ph.D
- Phone Number: +86-15091095796
- Email: rutaowang@qq.com
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710032
- Recruiting
- Ling Tao
-
Contact:
- Rutao Wang, M.D., Ph.D.
- Phone Number: +86-15091095796
- Email: rutaowang@qq.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with aortic valve disease are evaluated by the cardiac team and indicate TAVR therapy
- Patients who understand the purpose of this study, voluntarily participate in the trial and sign the informed consent form
Exclusion Criteria:
- Patients with aortic valve disease who have been evaluated by a cardiac team as unsuitable for TAVR
- Patients who cannot tolerate the materials or medications associated with this study
- Women who are pregnant or breastfeeding
- Patients who participated in a clinical trial of another drug or medical device before enrollment
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Combined early safety and clinical efficacy outcomes as defined by the Valve Academic Research Consortium-3 (VARC-3)
Time Frame: 1 year
|
Composed by all-cause mortality, all strokes, any hospitalization, myocardial infarction
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Combined early safety and clinical efficacy outcomes as defined by the Valve Academic Research Consortium-3 (VARC-3)
Time Frame: 30 days
|
Composed by all-cause mortality, all strokes, any hospitalization, myocardial infarction, acute kidney injury, life-threatening or fatal bleeding, mild or greater prosthetic valve regurgitation, new permanent pacemaker implantation, conduction block and arrhythmia, vascular and access-related complications, structural cardiac complications, any other adverse events
|
30 days
|
Combined safety and clinical efficacy outcomes as defined by the Valve Academic Research Consortium-3 (VARC-3)
Time Frame: 2 years, 3 years, 4 years
|
Composed by all-cause mortality, all strokes, any hospitalization, myocardial infarction, life-threatening or fatal bleeding, mild or greater prosthetic valve regurgitation, new permanent pacemaker implantation, conduction block and arrhythmia, any other adverse events
|
2 years, 3 years, 4 years
|
Combined safety and clinical efficacy outcomes as defined by the Valve Academic Research Consortium-3 (VARC-3)
Time Frame: 5 years and 10 years
|
Composed by all-cause mortality, all strokes, any hospitalization, myocardial infarction, life-threatening or fatal bleeding, mild or greater prosthetic valve regurgitation, new permanent pacemaker implantation, conduction block and arrhythmia, structural valve deterioration, any other adverse events
|
5 years and 10 years
|
Rate of technical success
Time Frame: at exit from procedure room
|
Technical success
|
at exit from procedure room
|
Rate of device success
Time Frame: discharge or 30 days
|
Device success
|
discharge or 30 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Ling Tao, M.D, Ph.D, Xijing Hospital
- Study Chair: Rutao Wang, M.D, Ph.D, Xijing Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RECORD TAVR REGISTRY
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Valve Disease Mixed
-
University Hospital Inselspital, BerneRecruiting
-
Assistance Publique - Hôpitaux de ParisEuropean Association of Cardiovascular ImagingNot yet recruitingAortic Valve Stenosis | Aortic Valve Disease | Heart Valve Diseases | Mitral Valve Insufficiency | Aortic Valve Insufficiency | Mitral Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Tricuspid Valve Insufficiency | Mitral Valve Disease | Tricuspid Valve Disease | Mitral Valve Insufficiency and... and other conditionsFrance
-
Beth Israel Deaconess Medical CenterBrigham and Women's HospitalRecruitingAortic Valve Disease | Aortic Valve Insufficiency | Aortic Aneurysm | Aortic Diseases | Aortic Valve Calcification | Calcific Aortic Stenosis | Calcific Aortic Stenosis - Bicuspid Valve | Aortic Valve Cusp Abnormality | Aortic Valve Disease MixedUnited States
-
Boston Children's HospitalRecruitingValve Disease, Heart | Valve Heart Disease | Valve Disease, AorticUnited States
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaTerminatedAortic Regurgitation | Aortic Valve Insufficiency | Regurgitation, Aortic Valve | Aortic Valve | Aortic IncompetenceKorea, Republic of
-
Genesis Medtech CorporationRecruiting
-
Assistance Publique Hopitaux De MarseilleSuspendedAortic Valve Regurgitation AcquiredFrance
-
The Cleveland ClinicRecruitingAortic Stenosis | Aortic Regurgitation | Valve Heart DiseaseUnited States
-
Na Homolce HospitalCentre of Cardiovascular and Transplantation Surgery, Czech Republic; St. Anne... and other collaboratorsRecruitingAortic Valve RegurgitationSerbia, Czechia, Belgium
-
Han Yaling, MDRecruitingCardiac Rehabilitation | Valve Disease, AorticChina
Clinical Trials on Transcatheter aortic valve replacement
-
IRCCS Policlinico S. DonatoRecruiting
-
Clinique PasteurUnknownBicuspid Aortic ValveFrance
-
Ole De BackerBoston Scientific Corporation; Abbott; Edwards Lifesciences; Symetis SAActive, not recruitingHeart Diseases | Cardiovascular Diseases | Aortic Valve Stenosis | Heart Valve Diseases | Ventricular Outflow ObstructionFinland, Norway, Sweden, Denmark, Iceland
-
Didier TCHETCHEAbbottNot yet recruitingBicuspid Aortic ValveFrance
-
University of PadovaFondazione GISE OnlusRecruiting
-
OptimapharmEdwards LifesciencesActive, not recruitingAortic Valve Stenosis | Heart Valve DiseasesUnited Kingdom, Italy, Germany, France, Austria, Switzerland, Finland, Czechia, Belgium, Netherlands, Cyprus, Ireland
-
Xijing HospitalRecruitingAortic Valve RegurgitationChina
-
Xijing HospitalRecruiting
-
Medical University of WarsawRecruitingAortic Valve Stenosis | Ventricular Outflow Obstruction, LeftPoland
-
Segeberger Kliniken GmbHCompleted